Retronecine N-oxide
Reference standards.
Inquire / Order:
manager@chemfaces.com
Technical Inquiries:
service@chemfaces.com
Tel:
+86-27-84237783
Fax:
+86-27-84254680
Address:
1 Building, No. 83, CheCheng Rd., Wuhan Economic and Technological Development Zone, Wuhan, Hubei 430056, PRC
Providing storage is as stated on the product vial and the vial is kept tightly sealed, the product can be stored for up to
24 months(2-8C).
Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20C. Generally, these will be useable for up to two weeks. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.
Need more advice on solubility, usage and handling? Please email to: service@chemfaces.com
The packaging of the product may have turned upside down during transportation, resulting in the natural compounds adhering to the neck or cap of the vial. take the vial out of its packaging and gently shake to let the compounds fall to the bottom of the vial. for liquid products, centrifuge at 200-500 RPM to gather the liquid at the bottom of the vial. try to avoid loss or contamination during handling.
Pak J Pharm Sci.2018, 31:311-315
Molecules.2019, 24(1):E159
Chem Res Toxicol.2023, 36(2):213-229.
Nat Commun.2019, 10(1):2745
Nat Commun.2023 Dec 20;14(1):8457.
Arch Toxicol.2024, 98(5):1415-1436.
UDC.2020, 19(4).
Front Chem.2023, 11:1245071.
Phytomedicine.2018, 38:12-23
Plant Science2024, 338:111914
Related and Featured Products
Toxicol Ind Health. 2008 Apr;24(3):181-8.
Metabolic activation of retronecine and retronecine N-oxide - formation of DHP-derived DNA adducts.[Pubmed:
18842697 ]
The metabolism of Retronecine N-oxide under similar conditions also formed the similar set of DHP-DNA adducts.
METHODS AND RESULTS:
The level of DNA adducts from retronecine was enhanced when metabolism by liver microsomes from phenobarbital (PB)-induced rats were used. The DHP-DNA adducts were also found in the liver DNA of female F344 rats treated with retronecine or Retronecine N-oxide. The highest level of the total DHP-DNA adducts was found in liver DNA from the rats treated with dehydroretronecine (DHR). The order of the levels of DNA adducts in the liver DNA samples from rats treated with various pyrrolizidine alkaloids was: DHR > riddelliine > riddelliine N-oxide >> retronecine > Retronecine N-oxide.
CONCLUSIONS:
The results indicate that 1) retronecine can be metabolized to form DHP by rat liver microsomal enzymes and interacts with DNA to produce DHP-DNA adducts and 2) Retronecine N-oxide undergoes the biotransformation to the parent compound, retronecine. The results from this and our previous findings strongly suggest that formation of DHP-DNA adducts may be a potential biomarker for pyrrolizidine alkaloid carcinogenesis.
